ENTEST BIOMEDICAL, INC. (OTCMKTS:ENTB) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation
On May 23, 2017 Entest Biomedical, Inc. (the Company) amended
Article 4 of the Companys Articles of Incorporation to be and
read as follows:
4.Authorized Shares:
The aggregate number of shares, which the corporation shall have
authority to issue, shall consist of 500,000,000 shares of Common
Stock having a $.0001 par value, and 5,000,000 shares of
Preferred Stock having a $.0001 par value and 3,000,000 shares of
Non Voting Convertible Preferred Stock having a $1.00 par value.
Non Voting Convertible Preferred Stock shall convert at the
option of the holder into shares of the corporations common stock
at a conversion price equal to the greater of (i) $0.01 per share
or (ii) seventy percent (70%) of the lowest Closing Price for the
five (5) trading days immediately preceding written receipt by
the corporation of the holders intent to convert.
CLOSING PRICE shall mean the closing bid price for the
corporations common stock on the Principal Market on a Trading
Day as reported by Bloomberg Finance L.P.
PRINCIPAL MARKET shall mean the principal trading exchange or
market for the corporations common stock.
TRADING DAY shall mean a day on which the Principal Market shall
be open for business.
The Common and/or Preferred Stock of the Company may be issued
from time to time without prior approval by the stockholders.The
Common and/or Preferred Stock may be issued for such
consideration as may be fixed from time to time by the Board of
Directors- The Board of Directors may issue such share of Common
and/or Preferred Stock in one or more series, with such voting
powers, designations, preferences and rights or qualifications,
limitations or restrictions thereof as shall be stated in the
resolution or resolutions.
Item 9.01 Financial Statements and Exhibits.
EXHIBIT INDEX
| Exhibit 3(i) | Text of Amendment to Certificate of Incorporation |
About ENTEST BIOMEDICAL, INC. (OTCMKTS:ENTB)
Entest BioMedical, Inc. is engaged in the development and commercialization of immunotherapeutic therapies for the veterinary market, as well as the acquisition and operation of veterinary hospitals. The Company is engaged in the development and commercialization of ImenVax, a therapeutic cancer vaccine for use in canines, and the development and commercialization of certain intellectual property for non-human veterinary therapeutic use. Its products include ImenVax I, ImenVax II, ImenVax III and ENT-576. ImenVax I is a therapeutic for canine cancer, which involves isolating tumor cells from the patient and then placing the cells into a cell implant device that is inserted subcutaneously into the patient. ImenVax II is in early-stage of development. ImenVax III is intended to function by harnessing the ability of placental extracts to combat canine cancers. It is developing ENT-576 for the treatment of chronic obstructive pulmonary disease (COPD). ENTEST BIOMEDICAL, INC. (OTCMKTS:ENTB) Recent Trading Information
ENTEST BIOMEDICAL, INC. (OTCMKTS:ENTB) closed its last trading session up +0.0040 at 0.0340 with 84,021 shares trading hands.
